MODERN THERAPEUTIC APPROACHES IN EPILEPSY

Kamolabonu Rasuljon qizi Inomova

Andijan State Medical Institute, 6th-year student

E-mail: inamovak17@gmail.com

ORCID: https://orcid.org/0009-0005-4285-4578

Abstract

Epilepsy is one of the most common chronic neurological disorders, affecting people of all ages and imposing a substantial burden on patients, families, and health systems worldwide. Over the past two decades, the therapeutic landscape of epilepsy has expanded considerably, moving beyond traditional antiseizure medications toward precision medicine, targeted neurostimulation, and dietary and surgical interventions for drug-resistant cases. This article reviews current evidence on the epidemiology, classification, pathophysiology, and diagnostic approach to epilepsy, with particular emphasis on modern pharmacological and non-pharmacological treatment strategies, including newer antiseizure medications, ketogenic dietary therapy, epilepsy surgery, neurostimulation techniques, and emerging precision-medicine approaches.

Keywords

Epilepsy; Seizures; Antiseizure Medications; Drug-Resistant Epilepsy; Ketogenic Diet; Epilepsy Surgery; Neurostimulation; Precision Medicine.

Introduction

Epilepsy is a chronic neurological disorder characterized by an enduring predisposition to generate recurrent, unprovoked epileptic seizures, along with the associated neurobiological, cognitive, psychological, and social consequences of this condition. It is among the most common serious neurological disorders worldwide, affecting individuals across all age groups, socioeconomic backgrounds, and geographic regions. Despite substantial advances in diagnosis and treatment, a significant proportion of patients continue to experience seizures despite adequate pharmacological therapy, underscoring the need for continued research into more effective and individualized therapeutic strategies.

Epidemiology and Classification

Epilepsy affects a substantial proportion of the global population, with the highest burden observed in low- and middle-income countries, where access to diagnosis and treatment remains limited. The International League Against Epilepsy (ILAE) has established a widely used classification framework that categorizes seizures according to their onset (focal, generalized, or unknown) and epilepsy syndromes according to etiology, which may be structural, genetic, infectious, metabolic, immune, or unknown. Accurate classification is essential, as it directly informs the selection of appropriate antiseizure therapy.

Pathophysiology

The pathophysiology of epilepsy involves an imbalance between excitatory and inhibitory neurotransmission within cortical and subcortical neuronal networks. Abnormal synchronization of neuronal firing, alterations in ion channel function, and disruption of gamma-aminobutyric acid (GABA)-mediated inhibitory signaling are central mechanisms underlying seizure generation. Genetic mutations affecting ion channels and neurotransmitter receptors have been identified in a growing number of epilepsy syndromes, contributing to the emerging field of precision medicine in epilepsy care.

Diagnosis

The diagnosis of epilepsy is primarily clinical, based on a detailed history of seizure semiology, often supplemented by eyewitness accounts. Electroencephalography (EEG) remains a cornerstone diagnostic tool, providing evidence of epileptiform activity and assisting in syndrome classification. Magnetic resonance imaging (MRI) is essential for identifying structural abnormalities, such as hippocampal sclerosis, cortical dysplasia, or tumors, which may serve as the underlying substrate for seizures. In selected cases, video-EEG monitoring, genetic testing, and metabolic screening may be warranted to establish a precise diagnosis.

Pharmacological Treatment

Antiseizure medications (ASMs) remain the first-line treatment for the majority of patients with epilepsy. Older-generation agents, including valproate, carbamazepine, and phenytoin, remain widely used and effective for many seizure types, though they are associated with notable drug interactions and adverse effect profiles. Newer-generation ASMs, such as levetiracetam, lamotrigine, lacosamide, perampanel, and brivaracetam, offer improved tolerability and more favorable pharmacokinetic profiles, with fewer drug-drug interactions. Selection of an appropriate ASM depends on seizure type, epilepsy syndrome, patient age, comorbidities, and potential for teratogenicity in women of childbearing potential.

Approximately one-third of patients with epilepsy do not achieve adequate seizure control despite trials of two or more appropriately selected and adequately dosed ASMs, a condition termed drug-resistant epilepsy. These patients warrant early referral to specialized epilepsy centers for consideration of non-pharmacological treatment options.

Non-Pharmacological Treatment

Epilepsy Surgery

For patients with drug-resistant focal epilepsy and a clearly identified epileptogenic zone, resective surgery can achieve seizure freedom in a substantial proportion of carefully selected candidates, particularly in cases of temporal lobe epilepsy associated with hippocampal sclerosis. Comprehensive presurgical evaluation, including video-EEG monitoring, neuroimaging, and neuropsychological assessment, is essential to identify appropriate surgical candidates and minimize postoperative risk.

Neurostimulation

Neurostimulation techniques offer alternative options for patients who are not candidates for resective surgery. Vagus nerve stimulation (VNS) involves intermittent electrical stimulation of the vagus nerve and has demonstrated efficacy in reducing seizure frequency across a range of epilepsy syndromes. Responsive neurostimulation (RNS) and deep brain stimulation (DBS), particularly targeting the anterior nucleus of the thalamus, represent more recently developed approaches that provide targeted, closed-loop or continuous stimulation to disrupt seizure activity.

Dietary Therapy

The ketogenic diet, a high-fat, low-carbohydrate dietary regimen, has demonstrated efficacy in reducing seizure frequency, particularly in children with drug-resistant epilepsy and specific genetic epilepsy syndromes. Modified variants, including the modified Atkins diet and low glycemic index treatment, offer more palatable alternatives with comparable efficacy in select populations.

Precision Medicine and Emerging Therapies

Advances in genetic testing have enabled the identification of specific gene mutations underlying certain epilepsy syndromes, opening the door to targeted therapeutic approaches. For example, patients with SCN1A-related Dravet syndrome may benefit from specific ASMs while avoiding sodium channel blockers that can worsen seizures. Cannabidiol has received regulatory approval for the treatment of seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, representing a notable advance in targeted therapy for these historically difficult-to-treat conditions.

Discussion

The management of epilepsy has evolved substantially from a one-size-fits-all pharmacological approach toward an individualized treatment paradigm that integrates seizure type, underlying etiology, genetic findings, and patient-specific factors. While newer-generation ASMs have improved tolerability, drug-resistant epilepsy remains a significant clinical challenge, highlighting the importance of timely referral to specialized epilepsy centers for consideration of surgical, neurostimulation, or dietary interventions. Continued research into the genetic and molecular underpinnings of epilepsy holds promise for further expanding precision-medicine approaches and improving long-term outcomes for patients with this complex and heterogeneous disorder.

Conclusion

Epilepsy remains a common and clinically heterogeneous neurological disorder requiring individualized management. Modern therapeutic approaches, encompassing newer pharmacological agents, epilepsy surgery, neurostimulation, dietary therapy, and precision-medicine strategies, have considerably broadened the treatment options available to patients, particularly those with drug-resistant disease. Early and accurate diagnosis, coupled with timely referral to specialized epilepsy care when appropriate, remains essential for optimizing seizure control and improving patients’ quality of life.

Conflict of Interest

The author declares no conflict of interest.

References

1. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia. 2017.

2. World Health Organization. Epilepsy. Geneva: WHO; 2024.

3. Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019.

4. Devinsky O, Vezzani A, O’Brien TJ, et al. Epilepsy. Nat Rev Dis Primers. 2018.

5. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000.

6. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs. JAMA Neurol. 2018.

7. Rho JM. How does the ketogenic diet induce anti-seizure effects? Neurosci Lett. 2017.

8. Fisher RS. Deep brain stimulation of thalamus for epilepsy. Neurobiol Dis. 2023.

9. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017.